Electronic Cigarettes and Reactivity to Smoking Cues
The purpose of this study is to determine whether electronic cigarettes can reduce reactivity to smoking-related cues.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
|Official Title:||Electronic Cigarettes and Reactivity to Smoking Cues|
- Reduction in Cue Reactivity [ Time Frame: 2 weeks after use ] [ Designated as safety issue: No ]Outcomes will be measured using a battery of self-report, neuroimagning, and behavioral measures of cue-reactivity.
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||January 2015|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
Experimental: Dual nicotine patch and electronic cigarette
Nicotine patch and the electronic Cigarette will be administered.
|Other: Dual nicotine patch and electronic cigarette|
Tobacco-related illness causes over 5 million deaths per year in the developed world, and most currently available smoking cessation treatments do not effectively enhance long-term cessation outcomes. Reactivity to smoking cues is one factor associated with relapse vulnerability, which is untreated by cessation aids such as NRT. Combining treatments, which ameliorate both pharmacological nicotine withdrawal and reduce smoking cue reactivity, may enhance smoking cessation success. During this study we will test whether combining NRT with non-nicotine containing electronic cigarettes (e-cigarettes) effectively reduces reactivity to smoking cues. The only source of nicotine participants will receive during the study will come from NRT. We will use e-cigarettes that provide no nicotine, yet may provide a similar experience to smoking as e-cigarettes taste and feel similar to a regular cigarette. However, since nicotine delivery is not associated with the act of smoking the reinforcing effects associated with smoking behavior may be reduced. Reactivity to smoking cues will be assessed using a battery of measures including: self-report, behavioral, and neuroimaging.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01782599
|Contact: Stacey Farmer, BA||617-855-2359||Stacey Farmer <email@example.com>|
|United States, Massachusetts|
|Mclean Hospital Imaging Center||Recruiting|
|Belmont, Massachusetts, United States, 02478|
|Contact: Stacey Farmer, BA 617-855-2359|
|Principal Investigator: AMy C Janes, PhD|
|Principal Investigator:||Amy C Janes, PhD||Mclean Hospital|